Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
$96.00
-$4.73(-3.73%)
At close: 4:00 PM EST
$96.00
-$4.73(-3.73%)
Day’s Range― - ―
52-Week Range$81.20 - $129.27
Previous CloseN/A
Volume316.50K
Average Volume (3M)905.33K
Market Cap
$23.11B
Enterprise Value$7.11B
Total Cash (Recent Filing)$14.53B
Total Debt (Recent Filing)$245.40M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 10, 2026EPS Estimate
-0.25Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding240,455,440
10 Day Avg. Volume1,148,891
30 Day Avg. Volume905,326
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.36
Price to Sales (P/S)9.62
P/FCF Ratio-108.15
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit2.73
Enterprise Value/Ebitda-68.81
Forecast
1Y Price Target
$139.27Price Target Upside45.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy Of GotistobartGotistobart's profile appears promising with the therapy outperforming docetaxel in initial Ph 3 Preserve-003 data.
Financial PerformanceBioNTech reported Q3 revenues of €1,519M, beating consensus, primarily driven by revenues related to BNTX's recent collaboration with BMY.
Oncology PipelineBioNTech is successfully transitioning to becoming a fully integrated oncology company, making COVID-19 revenues a near-term, but not a long-term driver.
Bears Say
Clinical Pipeline DelaysThe clinical pipeline is advancing consistently slower than management's guidance with an ongoing trend of pushing out key catalysts.
COVID Vaccine Sales PressureUpdated CDC guidance on COVID vaccines for young and healthy individuals may pressure sales, but older patients and those with underlying conditions make up the bulk of revenues.
Market DynamicsCOVID-19 vaccine market dynamics and shifting policy remain a headwind.
BioNTech SE News
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $81.20 and its highest was $129.27 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $23.11B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2026 which is in 94 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 03, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$1.109 by $0.969.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -0.25.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 240,455,440 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$0.14 in its last earnings report, beating expectations of -$1.109. Following the earnings report the stock price went up 0.048%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$139.27 (45.07% Upside)
$139.27 (45.07% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $208.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.30%
12-Months-Change
Fundamentals
Return on Equity
-2.94%
Trailing 12-Months
Asset Growth
0.30%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BNTX Company Deck
BNTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
BioNTech showed strong progress in its oncology programs and financial position, highlighted by increased revenue and strategic advancements. However, challenges include significant financial losses and delays in product submissions due to regulatory discussions.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$139.27
▲(45.07% Upside)
Technical Analysis
Ownership Overview
0.36% Insiders
5.23% Mutual Funds
10.50% Other Institutional Investors
83.12% Public Companies and
Individual Investors